EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory

Annie Yang, Zhifang Zhang, Anthony K Park, Shyambabu Chaurasiya, Sang-In Kim, Jianming Lu, Yoya Vashi, Jennifer Cillis, Hannah Valencia, Courtney Chen, Supriya Deshpande, Yuman Fong und 1 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-014530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Annie Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Depratment of Surgery, City of Hope National Medical Center, Duarte, California, USA. Hauptthemen laut MEDLINE: Stomach Neoplasms, Peritoneal Neoplasms, Immune Checkpoint Inhibitors, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Surgery Start-Up Grant City of Hope.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peritoneal metastasis (PM) from gastric cancer (GC) is associated with poor prognosis and limited treatment options. We investigated a novel peritoneal-targeted therapy using CF33-human sodium iodide symporter (hNIS), a chimeric orthopoxvirus, combined with anti-PD-L1 immune checkpoint blockade in an immunocompetent mouse model of GCPM.

Methods

We evaluated replication and cytotoxicity of CF33-hNIS in human and murine GC cell lines. We assessed a syngeneic mouse model of PM using the transgenic mouse GC ACKPY3944 cells to test the efficacy of intraperitoneal (IP) CF33-hNIS alone and combined with intravenous or IP anti-PD-L1. Next, we performed flow cytometry and immunohistochemistry to analyze immune cell populations of CD3 + T cell subsets in the peritoneal cavity and tumor microenvironment. Mice that showed complete tumor regression (CTR) were rechallenged with ACKPY3944 cells to assess memory T cell responses.

Results

CF33-hNIS efficiently infected and killed GC cells. In vivo, IP CF33-hNIS alone significantly prolonged survival and increased infiltration of CD3 + and CD8 + T cells within the peritoneal cavity and solid tumor. The most pronounced therapeutic effect was observed with a single high-dose of CF33-hNIS (10 8 plaque-forming units) combined with IP anti-PD-L1 (Combo 2) with 75% CTR. Notably, mice with CTR rejected tumor rechallenge, exhibiting significantly elevated effector and central memory T cell populations in the peritoneal cavity and spleen. IP CF33-hNIS demonstrates robust anti-tumor efficacy against GCPM, particularly when combined with IP anti-PD-L1 in the high-dose Combo 2 regimen.

Conclusions

These findings support a simplified, high-dose IP treatment strategy to overcome immune resistance in GCPM and provide a strong rationale for future clinical evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsPeritoneal NeoplasmsImmune Checkpoint InhibitorsB7-H1 AntigenSymportersOncolytic VirotherapyAnimalsMiceHumansSodium-Iodide SymportersCell Line, TumorImmunologic MemoryFemaleNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Combination therapyGastric CancerImmune Checkpoint InhibitorImmunotherapyOncolytic virus

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenSodium-Iodide SymportersSymporters

Autor:innen und Institutionen

  • Depratment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
  • Depratment of Surgery, City of Hope National Medical Center, Duarte, California, USA yhwoo@coh.org zhifangzhang04@yahoo.com.
  • Cancer Immunotherapeutics Program, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.

Förderung

  • Department of Surgery Start-Up Grant City of Hope

Zitieren

APA

Yang, A., Zhang, Z., Park, A. K., Chaurasiya, S., Kim, S. I., Lu, J., Vashi, Y., Cillis, J., Valencia, H., Chen, C., Deshpande, S., Fong, Y., & Woo, Y. (2026). Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014530

Vancouver

Yang A, Zhang Z, Park AK, Chaurasiya S, Kim SI, Lu J, et al. Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014530

BibTeX
@article{Yang2026,
  author = {Yang, Annie and Zhang, Zhifang and Park, Anthony K and Chaurasiya, Shyambabu and Kim, Sang-In and Lu, Jianming and Vashi, Yoya and Cillis, Jennifer and Valencia, Hannah and Chen, Courtney and Deshpande, Supriya and Fong, Yuman and Woo, Yanghee},
  title = {Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-014530}
}
Kostenlos starten →